CHMP recommends Abilify Maintena to reduce relapse in Schizophrenia
Otsuka and Lundbeck received a positive recommendation the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on 20 September 2013 that recommends marketing authorization for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation indicated for maintenance treatment of Schizophrenia in adult patients stabilized with oral aripiprazole.
Clinical trials demonstrated that Abilify Maintena reduced the risk of relapse in adult patients with Schizophrenia in comparison with placebo.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.